Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open-Label, Phase 2 Study of Givastomig (TJ033721) in Combination With Nivolumab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated CLDN18.2 Positive and PD-1L Positive Locally Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma

NCT07432295 is registered in ClinicalTrials.gov with I-Mab Biopharma US Limited as lead sponsor.

NCT NCT07432295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07432295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open-Label, Phase 2 Study of Givastomig (TJ033721) in Combination With Nivolumab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated CLDN18.2 Positive and PD-1L Positive Locally Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
I-Mab Biopharma US Limited
Phase
Phase 2
Overall status
Recruiting
Start date
February 11, 2026
Completion date
August 31, 2030
Enrollment
180 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, esophageal adenocarcinoma, gastric cancer, gastroesophageal junction carcinoma, metastatic cancer, solid tumor